What Is a TIPS Stent and Why Is It Used?

A TIPS (transjugular intrahepatic portosystemic shunt) is a metal stent placed inside the liver to create a new channel between two major veins, relieving dangerously high blood pressure in the portal vein system. It is not a stent in the way most people picture one, holding open a clogged artery. Instead, it punches a shortcut through liver tissue so that blood can bypass the scarred, resistant liver and flow directly from the portal vein into the hepatic vein and back to the heart. The procedure has become the most commonly performed portal-decompression procedure in the United States, largely replacing the open surgical shunts that once required major abdominal operations.¹

Why Portal Pressure Becomes Dangerous

The portal vein collects blood from your intestines, spleen, and stomach and delivers it to the liver for processing. In a healthy liver, blood flows through easily. Chronic liver disease changes that. Scarring from cirrhosis stiffens the liver’s internal architecture, and the tiny blood vessels inside the liver narrow and distort. The result is a traffic jam: blood backs up behind the liver, and pressure in the portal vein climbs well above normal.²

As that pressure rises, the body tries to find alternate routes for the blood. Collateral vessels sprout, including fragile veins in the esophagus and stomach called varices. Meanwhile, arteries feeding the gut dilate, sending even more blood into the already overloaded portal system.³ The consequences of this pressure buildup include life-threatening bleeding from ruptured varices, accumulation of fluid in the abdomen (ascites), and kidney problems tied to the body’s distorted circulation. TIPS addresses the root hydraulic problem by lowering portal pressure directly.

How the Procedure Works

Despite creating a passage through the liver, TIPS does not require open surgery. An interventional radiologist threads a catheter through the internal jugular vein in the neck, advances it down through the heart and into one of the hepatic veins inside the liver. From there, a needle is pushed through liver tissue to reach the portal vein. Once that connection is established, a balloon widens the tract and a metal stent is deployed to hold the new channel open.⁴ The entire procedure happens under imaging guidance and typically takes one to three hours. Because there is no abdominal incision, recovery is far faster than with a surgical shunt.

The stent itself is a small mesh tube, usually around 8 to 10 millimeters in diameter. Modern versions are lined with a synthetic membrane (expanded polytetrafluoroethylene, or ePTFE) that dramatically improves how long the channel stays open compared with older bare-metal designs. Once in place, the stent immediately diverts a portion of portal blood flow into the systemic circulation, dropping portal pressure within minutes.

When TIPS Is Used for Variceal Bleeding

Ruptured esophageal or gastric varices can cause massive, sometimes fatal hemorrhage. The standard first-line treatment combines drugs that lower portal pressure with endoscopic banding of the bleeding veins. But when bleeding cannot be controlled, or when it recurs despite these measures, TIPS becomes critical. A landmark trial found that patients with advanced cirrhosis who received TIPS within 72 hours of a variceal bleed had a one-year survival of 86%, compared with 61% for those managed with drugs and endoscopic banding alone.⁵ In the same trial, rebleeding or failure to control bleeding occurred in only one early-TIPS patient versus fourteen in the standard-treatment group.

A separate randomized trial confirmed these findings, showing that early TIPS with covered stents improved transplant-free survival with a hazard ratio of 0.50 compared with standard care.⁶ The evidence is strong enough that current guidelines now recommend considering early (or “preemptive”) TIPS for patients with cirrhosis who present with high-risk variceal bleeding.

When TIPS Is Used for Refractory Ascites

Ascites, the buildup of fluid in the abdomen, is one of the most common and burdensome complications of cirrhosis. Diuretics and salt restriction control it in many patients, but some develop “refractory” ascites that no longer responds to medications or that recurs so rapidly the person needs repeated large-volume paracentesis, a procedure where liters of fluid are drained through a needle. TIPS attacks the underlying problem by lowering the pressure that drives fluid out of blood vessels and into the abdominal cavity.⁷

Beyond controlling fluid accumulation, TIPS also improves kidney function in these patients. After placement, urine output increases, sodium excretion rises, and the hormonal signals that drive fluid retention gradually calm down.⁷ Some evidence suggests that placing TIPS earlier in the course of refractory ascites, before patients become dependent on very frequent paracentesis, may prevent a downward spiral of worsening kidney function and increasingly uncontrollable fluid.⁸

TIPS Versus Repeated Paracentesis

For patients with refractory ascites, the practical choice often comes down to TIPS or continued large-volume paracentesis. A Cochrane review pooling data from multiple trials found that TIPS was far better at preventing ascites from coming back: at three months, the odds of reaccumulation were about 93% lower in the TIPS group. At 12 months, the advantage persisted. Mortality at 30 days and at two years, however, did not differ significantly between the two approaches. The tradeoff was a roughly twofold increase in the odds of hepatic encephalopathy in TIPS patients.⁹

Individual randomized trials have shown somewhat more encouraging survival results for TIPS. One trial found that TIPS was independently associated with better transplant-free survival in a multivariate analysis, and at three months about 61% of TIPS patients had no ascites at all compared with 18% of those managed with paracentesis.¹⁰ Another trial found two-year transplant-free survival of 59% in the TIPS group versus 29% in the paracentesis group, with paracentesis treatment independently predicting death.¹¹ The discrepancy between these individual trials and the pooled Cochrane analysis likely reflects differences in patient selection, stent type, and how closely patients were followed. In practice, the decision hinges on how sick the patient is, how well their liver is functioning, and how well they tolerate the risks of TIPS, particularly encephalopathy.

Covered Versus Bare-Metal Stents

The shift from bare-metal stents to covered stents has been one of the most important advances in TIPS history. Early bare-metal stents had a stubborn tendency to narrow and clog. Within weeks of placement, the body lines the inside of the stent with a layer of tissue called pseudointima. In bare stents, that layer keeps growing: smooth muscle cells proliferate and lay down collagen, gradually choking the channel.¹² Cells from stenotic (narrowed) stents actually proliferate faster and secrete more collagen than cells from stents that remain open, suggesting the process becomes self-reinforcing once it starts.¹³

Covered stents, which have a synthetic lining that acts as a barrier between the metal and the surrounding tissue, dramatically reduce this problem. A meta-analysis of randomized controlled trials found that covered stents improved both overall survival and shunt patency compared with bare stents.¹⁴ A single-center trial put specific numbers on the difference in narrowing: the five-year restenosis rate was about 36% with covered stents versus roughly 75% with bare stents.¹⁵ Another trial reported a 39% reduction in shunt dysfunction at two years with covered stents.¹⁶ The superiority is clear enough that covered stents are now the standard; bare-metal versions are rarely used.

Covered stents also improve bleeding outcomes. In a study spanning two decades, patients with covered stents had a rebleeding rate of 14% compared with 37% for those with bare stents. In multivariate analysis, stent type was the only independent predictor of rebleeding within the first year.¹⁷

The Encephalopathy Problem

The most common complication of TIPS is hepatic encephalopathy, a spectrum of brain dysfunction that ranges from subtle confusion and sleep disturbances to severe disorientation and coma. It happens because the shunt diverts blood around the liver, allowing toxins such as ammonia that the liver normally clears to reach the brain in higher concentrations.¹⁸ The majority of post-TIPS encephalopathy episodes respond to medical treatment, typically lactulose (which traps ammonia in the gut) and rifaximin (an antibiotic that reduces ammonia-producing bacteria). A small percentage of patients, roughly 3% to 7%, develop refractory encephalopathy that does not respond to these medications, and for them the shunt may need to be narrowed or closed using percutaneous techniques.¹⁹

The risk of encephalopathy is one of the main reasons researchers have been experimenting with smaller-diameter stents, which divert less blood away from the liver. A recent trial comparing 8-mm stents with 10-mm stents for variceal bleeding found that the smaller stents cut the one-year incidence of overt encephalopathy from about 45% to 29% without increasing bleeding risk or mortality.²⁰ Even smaller designs are being tested. A trial of 7-mm versus 8-mm stents in patients with small livers found that the 7-mm group had a two-year encephalopathy rate of about 21% compared with 37% for the 8-mm group, with no difference in rebleeding or survival.²¹ A separate trial comparing 6-mm and 8-mm stents found the encephalopathy advantage held at two years, with 20% in the 6-mm group versus 42% in the 8-mm group.²² The trend is clear: smaller shunts trade less portal decompression for significantly fewer brain-related side effects, and ongoing research is trying to pin down the ideal diameter for different patients.

Cardiac Stress After TIPS

TIPS does not just reroute blood within the abdomen; it significantly changes how much blood reaches the heart. By opening a low-resistance channel, the shunt increases the volume of blood returning to the right side of the heart. Cardiac imaging studies show measurable enlargement of all four heart chambers after TIPS placement.²³ Right atrial pressure and pulmonary artery pressure can jump substantially, and cardiac output increases in a sustained way. For a healthy heart, this added workload is usually manageable. But patients with cirrhosis often have an underlying cardiac condition called cirrhotic cardiomyopathy, where the heart’s ability to respond to increased demands is already blunted.

An estimated 10% to 25% of patients experience some degree of cardiac decompensation in the months following TIPS.²⁴ This is why cardiac evaluation before TIPS placement has become increasingly important. Echocardiography to assess heart function and pulmonary pressures is now a routine part of the pre-procedure workup, and patients with significant pre-existing heart failure are generally not candidates for the procedure.

Picking the Right Patient

Not everyone with portal hypertension is a good fit for TIPS. Patient selection is one of the strongest predictors of whether the procedure helps or harms. The Model for End-Stage Liver Disease (MELD) score, which reflects how well the liver and kidneys are functioning, has traditionally been used to gauge risk. Current guidelines generally recommend that elective TIPS for ascites be performed in patients with a MELD score of 18 or lower, although more recent data suggest that patients with scores up to 24 can benefit safely, likely because of improvements in stent technology, medical management, and patient selection criteria.²⁵

Newer scoring systems may refine risk prediction further. A study evaluating the updated MELD 3.0 score found that a cutoff of 14 could discriminate between high- and low-risk patients after TIPS, and that combining it with the older Child-Pugh classification provided additional stratification power.²⁶ In practice, the decision involves weighing liver function, kidney function, heart health, the severity of the complication being treated, and whether the patient is a candidate for liver transplantation. TIPS is sometimes placed specifically as a bridge to keep a patient stable while they wait for a donor organ.

The Pressure Sweet Spot

During and after TIPS placement, doctors measure the portal pressure gradient, the difference in pressure between the portal vein and the hepatic vein. Getting this number into the right range matters. Drop it too much and the liver loses too much of its blood supply, worsening liver failure and increasing the risk of encephalopathy. Drop it too little and the original problem, whether varices or ascites, comes back.

A multicenter study found that a post-TIPS portal pressure gradient below 7 mmHg was associated with higher liver-related death, while a gradient above 11 mmHg was linked to more ascites recurrence.²⁷ A separate retrospective analysis homed in further, suggesting that a gradient of 8 to 10 mmHg may be the sweet spot: patients in that range had the lowest rates of ascites recurrence, encephalopathy, and further decompensation compared with patients whose pressure dropped below 8 or stayed above 10.²⁸ This narrow therapeutic window helps explain why stent diameter and follow-up adjustments matter so much.

Monitoring After Placement

Once a TIPS is in place, it needs regular surveillance. Doppler ultrasound is the primary tool: it can measure the speed of blood flow through the stent and detect early signs of narrowing. Typical surveillance schedules call for an ultrasound within the first week, then at three months, six months, and every six months afterward.²⁹ Abnormal findings that trigger concern include stent velocities above 190 or below 90 cm/s, a velocity change of more than 50 cm/s from prior measurements, or the reappearance of blood flow patterns that suggest portal blood is no longer routing through the shunt.³⁰ If ultrasound suggests a problem, a direct venography (injecting contrast dye through the shunt under X-ray) can confirm whether the stent needs revision, usually by balloon dilation or placement of a new stent inside the old one.

Clinical symptoms are also important monitoring signals. The return of ascites, new or worsening variceal bleeding, or increasing abdominal girth between scheduled ultrasounds should prompt earlier imaging. Quality-of-life studies have shown that patients who maintain a functioning TIPS experience sustained improvement in how they feel over at least two years.³¹ When symptoms return, early investigation and intervention can preserve that benefit.

Less Common Uses

Beyond variceal bleeding and ascites, TIPS has a role in several other conditions driven by portal hypertension. Hepatic hydrothorax, where ascitic fluid migrates through defects in the diaphragm and accumulates in the chest, often responds to TIPS when diuretics and thoracentesis fail. Hepatorenal syndrome, a form of kidney failure triggered by the circulatory derangements of advanced cirrhosis, can also improve after TIPS because the procedure helps reverse the hormonal signals that constrict kidney blood flow.

Budd-Chiari syndrome, a rare condition in which the hepatic veins become blocked by blood clots, is another important indication. Because TIPS creates a new outflow tract through the liver, it can restore venous drainage even when the normal hepatic veins are obstructed. Studies have shown that TIPS effectively improves liver function and controls ascites in Budd-Chiari patients, and it can serve as a bridge to liver transplantation for those who ultimately need one.³² ³³

TIPS in Children

Pediatric patients with portal hypertension occasionally need TIPS, typically for variceal bleeding or severe ascites that is not controlled by other means. The procedure poses unique challenges in smaller bodies. Standard adult-sized stent-grafts may be too large for a child’s portal vein, but placing a fixed small-diameter stent creates the opposite problem: the child outgrows it.³⁴ Techniques have been developed to address this, including constrained stents that can be dilated later as the child grows and custom combinations of bare stents with smaller covered stent-grafts. One case report described successful long-term patency in an infant using a 6-mm covered stent-graft placed inside a bare stent, after the initial bare stent alone had occluded within 80 days.³⁵ Pediatric TIPS remains uncommon and is typically performed at specialized centers, but it offers a lifeline for children who would otherwise face surgical shunts or urgent transplantation.